Combined effect of atorvastatin and probucol on plasma cystatin C levels and severity of coronary lesion in patients with borderline coronary lesion

Chinese Medical Journal

Volumn 125, Issue 14, 2012, Pages 2472-2476

  Ge, Chang Jiang ^a   Lü, Shu Zheng ^a   Feng, Li Xia ^a   Huo, Yong ^b   Song, Xian Tao ^a   Chen, Xin ^a   Meng, Kang ^a   Yuan, Fei ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

Borderline coronary lesion; Coronary artery disease; Cystatin C

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CHOLESTEROL; CYSTATIN C; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROBUCOL; TRIACYLGLYCEROL;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; TREATMENT RESPONSE;

AGED; ANTICHOLESTEREMIC AGENTS; CORONARY DISEASE; CYSTATIN C; FEMALE; HEPTANOIC ACIDS; HUMANS; MALE; MIDDLE AGED; PROBUCOL; PROSPECTIVE STUDIES; PYRROLES;

EID: 84864239268     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2012.14.014     Document Type: Article

References (22)

1. Faxon DP, Fuster V, Libby P, Beckman JA, Hiatt WR, Thompson RW, et al. Atherosclerotic Vascular Disease Conference: Writing Group III: pathophysiology. Circulation 2004; 109: 2617-2625.
2. Casscells W, Naghavi M, Willerson JT. Vulnerable atherosclerotic plaque: a multifocal disease. Circulation 2003; 107: 2072-2075.
3. Ge CJ, Lu SZ, Chen YD, Wu XF, Hu SJ, Ji Y. Synergistic effect of Amlodipine and Atorvastatin on blood pressure, left ventricular remodeling and CRP in hypertensive patients with primary hypercholesterolemia. Heart Vessels 2008; 23: 91-95.
4. Li TT, Xie Y, Guo Y, Tian HB, Zhang JN, Peng J, et al. Effect of probucol on vascular remodeling due to atherosclerosis in rabbits: an intravascular ultrasound study. Chin Med J 2011; 124: 1840-1847.
5. Fujii K, Carlier SG, Mintz GS, Wijns W, Colombo A, Böse D, et al. Association of plaque characterization by intravascular ultrasound virtual histology and arterial remodeling. Am J Cardiol 2005; 96: 1476-1483.
6. Ge C, Ren F, Lu S, Ji F, Chen X, Wu X. Clinical prognostic significance of plasma cystatin C levels among patients with acute coronary syndrome. Clin Cardiol 2009; 32: 644-648.
7. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function-measured and estimated glomerular filtration rate. N Engl J Med 2006; 354: 2473-2483.
8. Sekizuka H, Akashi YJ, Kawasaki K, Yamauchi M, Musha H. Cystatin C: A better marker to detect coronary artery sclerosis. J Cardiol 2009; 54: 359-367.
9. Kestenbaum B, Psaty B, Tracy RP, Siscovick DS. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med 2006; 145: 237-246.
10. Antoniadis AP, Chatzizisis YS, Giannoglou GD. Pathogenetic mechanisms of coronary ectasia. Int J Cardiol 2008; 130: 335-343.
11. Eriksson P, Deguchi H, Samnegård A, Lundman P, Boquist S, Tornvall P, et al. Human evidence that the cystatin C gene is implicated in focal progression of coronary artery disease. Arterioscler Thromb Vasc Biol 2004; 24: 551-557.
12. Bengtsson E, Grubb A, Håkansson K, Wittgren L, Nilsson J, Jovinge S. Absence of the protease inhibitor cystatin C in inflammatory cells results in larger plaque area in plaque regression of apoE-deficient mice. Atherosclerosis 2005; 180: 45-53.
13. Shi GP, Sukhova GK, Grubb A, Ducharme A, Rhode LH, Lee RT, et al. Cystatin C deficiency in human atherosclerosis and aortic aneurysms. J Clin Invest 1999; 104: 1191-1197.
14. LI JJ. Inflammation: an importment mechanism for different clinical entities of coronary artery diseases. Chin Med J 2005; 118: 1817-1826.
15. Derosa G, D'Angelo A, Scalise F, Avanzini MA, Tinelli C, Peros E, et al. Comparison between metalloproteinases-2 and-9 in healthy subjects, diabetics, and subjects with acute coronary syndrome. Heart Vessels 2007; 22: 361-370.
16. Chen ZK, Ge CJ, Hu SJ. The relationship of cystatin C and cardiovascular diseases. Progress Physiol Sci (Chin) 2003; 34: 269-271.
17. Katsuda S, Kaji T. Atherosclerosis and extracellular matrix. J Atheroscler Thromb 2003; 10: 267-274.
18. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998; 98: 839-844.
19. Wu BJ, Di Girolamo N, Beck K, Hanratty CG, Choy K, Hou JY, et al. Probucol 4, 4'-[(1-methylethylidene) bis(thio)] bis-[2, 6-bis (1, 1-dimethylethyl) phenol] inhibits compensatory remodeling and promotes lumen loss associated with atherosclerosis in apolipoprotein E-deficient mice. J Pharmacol Exp Ther 2007; 321: 477-484.
20. Meng XP, Wang SX, Zhang JC, Li ZX, Geng L, Yin CY. Effects of probucol, aspirin and atorvastatin combination therapy upon atherosclerosis. Natl Med J China (Chin) 2009; 89: 1986-1988.
21. Endo K, Miyashita Y, Sasaki H, Ebisuno M, Ohira M, Saiki A, et al. Probucol and atorvastatin decrease urinary 8-hydroxy-2'-deoxyguanosine in patients with diabetes and hypercholesterolemia. J Atheroscler Thromb 2006; 13: 68-75.
22. Adameova A, Xu YJ, Duhamel TA, Tappia PS, Shan L, Dhalla NS. Anti-atherosclerotic molecules targeting oxidative stress and inflammation. Curr Pharm Des 2009; 15: 3094-3107.